-
Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID
T2B! immunity against SARS-CoV-2 study group, Kummer, L. Y. L., Kreher, C., Bos, A., Kuijper, L. H., Verstegen, N. J. M., van de Sandt, C. E., Konijn, V. A. L., Duurland, M. C., Menage, C., Jorritsma, T., Steenhuis, M., Hagen, R. R., van den Dijssel, J., de Jongh, R., Ashhurst, T., van Gils, M. J., Garcia-Vallejo, J. J., Claireaux, M. & Stalman, E. W. & 9 others, , Oct 2024, In: RMD open. 10, 4, 12 p., e004664.Research output: Contribution to journal › Article* › Academic › peer-review
-
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy
the T2B! immunity against SARS-CoV-2 study group, Schreurs, C. R. G., van der Pol, W. L., Goedee, H. S., Verstegen, N. J. M. & T2B! immunity against SARS-CoV-2 study group, Sept 2024, In: Journal of allergy and clinical immunology. 154, 3, p. 754-766.e7Research output: Contribution to journal › Article* › Academic › peer-review
-
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
T2B! immunity against SARS-CoV-2 study group, Verstegen, N. J. M., Hagen, R. R., Ashhurst, T., Palomares Cabeza, V., Steenhuis, M., Duurland, M. C., Jongh, R. D., Schoot, C. E. V. D., Mul, E., Kedzierska, K., van Dam, K. P. J., Stalman, E. W., Boekel, L., Tas, S. W., Killestein, J., Rispens, T., Kuijpers, T. W., Eftimov, F. & van Kempen, Z. L. E. & 11 others, , Sept 2024, In: Journal of Neurology, Neurosurgery and Psychiatry. 95, 9, p. 855–864 jnnp-2023-332224.Research output: Contribution to journal › Article* › Academic › peer-review
